• Cheng-Hsu Chen, En-Ling Yeh, Chih-Chung Chen, Shih-Chien Huang, and Yi-Chia Huang.
• Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
• Biomed Res Int. 2017 Jan 1; 2017: 7367831.

AbstractThe purpose of this study was to investigate whether plasma pyridoxal 5'-phosphate (PLP) and homocysteine were dependent on or independent of each other in order to be associated with inflammatory markers in patients with chronic kidney disease (CKD) or those receiving hemodialysis treatment. This was a cross-sectional study. Sixty-eight stage 2-5 CKD patients and 68 hemodialysis patients had one time fasting blood drawn for measurements of plasma PLP, pyridoxal (PL), homocysteine, and several inflammatory markers. Early CKD stage (stages 2-3) patients showed significantly lower plasma PLP levels and homocysteine concentrations than patients in an advanced CKD stage (stages 4-5) and those undergoing hemodialysis. Plasma PLP significantly correlated with CRP levels (partial r s = -0.21, p < 0.05) and plasma PL significantly correlated with IL-10 levels (partial r s = -0.24, p < 0.01), while plasma PLP plus PL significantly correlated with both CRP levels (partial r s = -0.20, p < 0.05) and interleukin-1β (partial r s = 0.22, p < 0.05) levels after adjusting for plasma homocysteine and other potential confounders. Plasma homocysteine displayed no significant correlations with any inflammatory markers. Vitamin B-6 status, rather than homocysteine, appeared to be a significant factor in relation to inflammatory responses for CKD and hemodialysis patients.

33 keywords...

hide…